Discontinuing Prophylactic Transfusions Used to Preven Stroke in Sickle Cell Disease
NEJM 353:2769-2778,2743, The Optimizing Primary Stroke Prevention in Sickle Cell Anemia (STOP 2) Trial Investigators, 2005
Safety of Tissue Plasminogen Activator for Acute Stroke in Menstruating Women
Stroke 33;2506-2508, Wein,T.H.,et al, 2002
Silent Infarcts in Children With Sickle Cell Anemia and Abnormal Cerebral Artery Velocity
Arch Neurol 58:2017-2021, Pegelow,C.H.,et al, 2001
Prevent of a 1st Stroke by Transfusions in Children/Sickle Cell Anemia & Abnorm Results on Transcr Doppler Ultrasonog
NEJM 339:5-11, Adams,R.J.,et al, 1998
The Use of Transcranial Ultrasonography to Predict Stroke in Sickle Cell Disease
NEJM 326:605-610, 6371992., Adams,R.,et al, 1992
Zika Virus as a Cause of Neurologic Disorders
NEJM 374:1506-1509, Broutet, N.,et al, 2016
Zika Virus: An Emergent Neuropathological Agent
Ann Neurol 80:479-489, White, M.K.,et al, 2016
Controlled Trial of Transfusions for Silent Cerebral Infarcts in Sickle Cell Anemia
NEJM 371:699-710, DeBaun, M.R.,et al, 2014
Discontinuation of Long-Term Transfusion Therapy in Patients with Sickle Cell Disease & Stroke
J Pediatr 131:757-760, Rana,S.,et al, 1997
Post-Transfusion Reversible Posterior Leukoencephalopathy Syndrome with Cerebral Vasoconstriction
Neurol 49:1174-1175, Ito,Y.,et al, 1997
Risk of Recurrent Stroke in Patients with Sickle Cell Disease Treated with Erythrocyte Transfusions
J Pediatr 126:896-899, Pegelow,C.H.,et al, 1995
Neurologic Events after Partial Exchange Transfusion for Priapism in Sickle Cell Disease
J Pediatr 120:882-885, Rackoff,W.R.,et al, 1992
High Risk of Recurrent Stroke after Discont of 5 to 12 Yrs of Transfusions in Sickle Cell Disease
J Pediatr 118:377-379, Wang,W.C.,et al, 1991
HTLV-I-Associated Myelopathy
NEJM 323:552, Engel,W.K.,et al, 1990